Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema

Trial Profile

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2015

At a glance

  • Drugs Brimonidine (Primary)
  • Indications Erythema
  • Focus Therapeutic Use
  • Sponsors Galderma
  • Most Recent Events

    • 05 Nov 2014 Status changed from not yet recruiting to withdrawn prior to enrolment according to ClinicalTrials.gov record.
    • 16 Sep 2014 Planned number of patients changed from 84 to 260 according to ClinicalTrials.gov record.
    • 16 Sep 2014 Planned End Date changed from 1 Feb 2015 to 1 Sep 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top